Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

"Real world" comparison favours angioplasty over thrombolytics

This article was originally published in Clinica

  • News

Executive Summary

At hospitals with angioplasty facilities, primary angioplasty should be the method of choice for treating acute myocardial infarction. This is the conclusion of the first "real world" comparison of primary angioplasty with intravenous thrombolysis based on data from 9,906 patients enrolled in two multicentre studies in Germany: the Maximal Individual TheRapy in Acute myocardial infarction (MITRA) study and the Myocardial Infarction Registry (MIR). Some 87% of patients received thrombolytics and 13% angioplasty.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Digital Health Roundup: US FDA’s ‘Idea Lab’; Philips’ Roy Jakobs On AI Draft Framework; Apple Watch

CDRH’s AR/VR Home Space Will Serve As An ‘Idea Lab’ For Device Stakeholders

EU Regulatory Roundup, April 2024: EU On Cusp Of Regulatory Shifts Amidst Political Change

Abbott Receives FDA Approval For Esprit BTK Drug-Eluting Resorbable Scaffold

See All
UsernamePublicRestriction

Register

MT071508

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By